Mode of Action and Onset of Effect of Daflon (MPFF)
Daflon (micronized purified flavonoid fraction) works through multiple vascular mechanisms including increasing venous tone, improving lymphatic drainage, reducing capillary hyperpermeability, and suppressing inflammatory processes in the vessel wall, with symptomatic improvement typically observed within days to weeks of initiating treatment.
Mechanism of Action
MPFF exerts its therapeutic effects through several interconnected pathways 1, 2, 3:
Venous and Lymphatic Effects
- Increases venous tone and elasticity - directly strengthens vein walls and improves their contractile function
- Enhances lymphatic drainage - reduces fluid accumulation in tissues
- Normalizes capillary permeability - prevents excessive fluid leakage from vessels
Anti-Inflammatory Properties
The drug's most critical mechanism involves suppressing the inflammatory cascade that drives venous disease progression 4, 2:
- Inhibits endothelial activation - prevents the initial trigger of inflammation in vessel walls
- Reduces leukocyte-endothelium interaction - blocks white blood cell adhesion and infiltration into vein walls
- Decreases granulocyte and macrophage infiltration - demonstrated in experimental models to protect valve structures 4
- Reduces proteolytic enzyme activity (MMP-2 and MMP-9) - prevents destruction of valve tissue 4
Microcirculatory Protection
- Protects capillaries from inflammatory damage - particularly important in advanced disease stages
- Improves hemorheological parameters - enhances blood flow characteristics 5
- Increases transcutaneous oxygen tension - improves tissue oxygenation 5
Onset of Effect
The timeline for clinical benefit varies by indication and severity:
Acute Hemorrhoids
- Rapid onset: 4-7 days - In acute internal hemorrhoids, symptom improvement occurs within the first week of treatment 1, 6
- Dosing: 3 tablets twice daily for 4 days, then 2 tablets twice daily for 3 days
Chronic Venous Insufficiency Symptoms
- Early improvement: 1-2 weeks - Patients report symptomatic relief of pain, heaviness, and discomfort within 2 weeks 1, 7
- Sustained benefit: 2 months - Objective measurements (leg circumference reduction, plethysmographic parameters) show significant improvement by 2 months 1, 5
Venous Ulcer Healing
- Accelerated healing: 2-6 months - When added to standard compression therapy, MPFF significantly shortens ulcer healing time compared to compression alone 6, 5
Disease Modification
- Preventive effects: ongoing - Animal studies demonstrate that MPFF can delay development of venous reflux and prevent valve destruction when initiated early 4, though long-term clinical data on disease progression are still needed 8
Clinical Dosing
Standard regimen: 500 mg twice daily (1000 mg total daily dose) 1, 6
Recent evidence shows 1000 mg once daily is equally effective as 500 mg twice daily for chronic venous disease, with similar patient compliance, efficacy, and adverse event profiles 9. This simplified dosing may improve adherence in real-world practice.
Important Caveats
- Not FDA-approved in the United States - MPFF is widely used in Europe and other countries but has not received FDA approval 1
- Adjunctive therapy - MPFF should complement, not replace, standard treatments like compression therapy for venous ulcers or appropriate interventions for hemorrhoids 6, 3
- Well-tolerated - Adverse events are primarily mild gastrointestinal symptoms, with a safety profile similar to placebo 6
The comprehensive mechanism targeting inflammation, venous tone, and microcirculation explains why MPFF demonstrates efficacy across all stages of chronic venous disease (C0s-C6) 7 and in hemorrhoidal disease 1, 10.